---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-23-000050"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2023-11-28T23:59:59+00:00"
generated_at: "2026-06-07T21:02:38.133823+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Novocure announces $60M cost-cutting plan, cuts 200 jobs (13% of workforce)

## Summary
- Reduction in residual operating expenses of ~$60M; includes 200 job cuts (13% of staff).
- One-time restructuring charge of ~$7M expected in Q4 2023.
- Pivots resources to launch readiness for metastatic NSCLC Tumor Treating Fields therapy.
- Plans two Phase 3 readouts in 2024: METIS (brain mets NSCLC) and PANOVA-3 (pancreatic).
- Prioritizes clinical trials TRIDENT, KEYNOTE D58, LUNAR-2 for greatest value.

## SEC filing metadata
- accession: 0001645113-23-000050
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2023-11-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000050/0001645113-23-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000050/nvcr-20231128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-23-000050
- JSON: https://secwatch.observer/filing/0001645113-23-000050.json
- Plain text: https://secwatch.observer/filing/0001645113-23-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.